Skip to content
OpenCapital
Get started

Catalyst Pharmaceutical CPRX Amortization of capitalized software and acquired intangible assets

Amortization of capitalized software and acquired intangible assets at other companies

Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
——
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
——

Other financials

Income statement

See full
Revenue$149.4M+5.6%
Gross profit$134.9M+9.2%
Operating income$73.2M+15.6%
Net income$63.7M+12.3%
EPS (diluted)$0.50+11.1%

Balance sheet

See full
Cash & equivalents$755.9M+30.2%
Total debt$2.7M-13.3%
Total equity$1.0B+27.5%
Total assets$1.1B+26.3%

Cash flow

See full
Operating cash flow$59.6M-0.8%
CapEx$27.0K—
Free cash flow$59.6M-0.8%

Valuation

See full
Market cap$3.84B+2.7%

Profitability

See full
Gross margin86%-0.2pp
Operating margin44.8%+1.6pp
Net margin37.1%+0.2pp
FCF margin34.9%-15.2pp

Returns & leverage

See full
Return on equity24.5%-4.6pp
Debt / equity0×0.0×
Current ratio7.1×+1.0×

Where this comes from

Reported directly by Catalyst Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Catalyst Pharmaceutical's amortization of capitalized software and acquired intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Catalyst Pharmaceutical's amortization of capitalized software and acquired intangible assets?
Catalyst Pharmaceutical (CPRX) reported amortization of capitalized software and acquired intangible assets of $9.7M in Q1 2026.
How has Catalyst Pharmaceutical's amortization of capitalized software and acquired intangible assets changed year-over-year?
Catalyst Pharmaceutical's amortization of capitalized software and acquired intangible assets increased by 3.8% year-over-year, from $9.35M to $9.7M.